INVESTORS Annual Reports Financials Investor Presentations Shareholder Information Analysts Speak Events Companies Act Policies
LUPIN FOUNDATION
CAREERS Careers Overview Life at Lupin Campus Connect Learning & Development Current Openings P.L.E.D.G.E.
MEDIA Press Releases Downloadables
CONTACT US Contact Us Global Offices Partner With Us Lupin for Suppliers

FEATURED

2018 ▼
2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002

Lupin Receives Tentative Approval for Generic Livalo® Tablets

December 30, 2016

Lupin Receives Tentative Approval for Generic Giazo® Tablets

December 29, 2016

Lupin Receives Tentative Approval for Generic Benicar® Tablets

December 26, 2016

Lupin Launches Generic Vfend® Tablets and Vfend® Oral Suspension in the US

December 19, 2016

Lupin Receives FDA Approval for Generic Topicort® Ointment, 0.05%

December 14, 2016

Lupin Receives Tentative Approval for Generic Zorvolex® Capsules

December 6, 2016

Lupin Receives FDA Approval for Generic Norco® Tablets

December 5, 2016

Lupin and Eli Lilly Expand Partnership in India

December 1, 2016

Lupin Receives FDA Approval for Generic Nuvigil® Tablets

November 29, 2016

Lupin Receives Tentative Approval for Generic Epzicom® Tablets

November 23, 2016

Lupin Receives FDA Approval for Hydrocodone Bitartrate and Acetaminophen Tablets

November 17, 2016

Lupin Launches Generic Activella® Tablets in the US

November 15, 2016

Lupin Launches Novel Injectable Iron Formulation Under Brand Names “ISOFER” and “JILAZO” in India

November 11, 2016

Lupin's Quarter II, FY2017 - Results

November 9, 2016

Lupin receives EIR from US FDA for Goa, March 2016 Inspection

November 4, 2016

Lupin Receives FDA Approval for Generic Ortho-Cyclen® 28 Tablets

November 1, 2016

Notice to the Exchanges on Board Meetings.

October 18, 2016

Type 2 Diabetes: Boehringer Ingelheim India and Lupin Announce Strategic Co-marketing Agreement

October 13, 2016

Lupin and Monosol Rx announce licensing agreement for multiple pediatric-focused products

October 6, 2016

Lupin Receives FDA Approval for Generic Namenda XR® Capsules

September 29, 2016

Lupin Receives Tentative Approval for Generic Rapaflo® Capsules

September 6, 2016

Lupin Receives Tentative Approval for Generic Avelox® Tablets

September 6, 2016

Lupin Receives Tentative Approval for Generic Zithromax® Oral Suspension

September 1, 2016

Lupin Receives Tentative Approval for Generic Paxil CR® Tablets

August 26, 2016

Lupin Receives FDA Approval for Generic Zyvox® Tablets

August 24, 2016

Lupin Receives Approval for Acotiamide Tablets to Treat Functional Dyspepsia

August 22, 2016

Lupin Receives FDA Approval for Potassium Chloride Extended-Release Capsules

August 17, 2016

Notice to the Exchanges on Board Meeting

August 11, 2016

Lupin Receives FDA Approval for Generic Klor-Con® Extended-Release Tablets

August 10, 2016

Record Sales & Profits - Quarter I FY2017

August 9, 2016

Lupin Acquires Branded Product Portfolio from Shionogi in Japan

August 2, 2016

Lupin Receives Tentative Approval for Generic Lexiva® Tablets, 700 mg from US FDA

July 27, 2016

Lupin Launches Generic Ortho Tri-Cyclen® Tablets in the US

July 20, 2016

US FDA Audit at Lupin’s Dabhasa Facility, 29th June – 06th July 2016

July 8, 2016

Lupin receives EIR from US FDA for Goa, July 2015 Inspection

July 7, 2016

Lupin Receives FDA Approval for Generic Activella® Tablets

June 22, 2016

Lupin Appoints Yugesh Goutam as President – Global HR

June 7, 2016

Lupin Receives FDA Approvals for Generic Vfend® Tablets 50mg, 200mg & Vfend® Oral Suspension, 40 mg/mL

June 6, 2016

Lupin announces closure of US FDA Audits for its Mandideep and Aurangabad Facilities

May 26, 2016

Record Sales & Profits – A New High Quarter IV & Annual Results - FY2016 Q4 FY2016 Net Sales up 34.0%, EBITDA up 72.7%, Net profit up 47.5% Proposed Dividend 375%

May 19, 2016

Notice to the Exchanges on Board Meetings

May 4, 2016

Lupin Launches Generic Femhrt® Tablets in the US

April 18, 2016

Lupin to Market new Inhaler under the brand name Loftair® in India

April 11, 2016

Lupin named amongst AON Best Employers India 2016

April 5, 2016

Lupin Appoints Dr. Kurt Nielsen as President of Lupin - Somerset

April 5, 2016

Lupin Launches Generic Intermezzo® Sublingual Tablets in the US

April 5, 2016

Lupin launches Generic Aricept tablets in the US

March 31, 2016

Disclosures to the Exchanges on Mandideep US FDA Audit

March 29, 2016

Disclosures to the Exchanges on Goa US FDA Audit

March 15, 2016

Lupin Completes its Acquisition of GAVIS

March 9, 2016

Lupin Limited - Quarter III Results, FY2016

February 5, 2016

Lupin Launches Generic Glumetza® HCI ER Tablets in the US

February 2, 2016

Notice to the Exchanges on Board Meetings

January 19, 2016

Lupin Receives FDA Approval for Generic Generess® Tablets

January 8, 2016

Lupin Launches Generic Ortho Tri-Cyclen® Lo Tablets

January 6, 2016